|
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
|
Written by: J. Smith |
Hits: 232
|
|
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
|
Written by: J. Smith |
Hits: 324
|
|
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
|
Written by: J. Smith |
Hits: 295
|
|
CVS Caremark Faces Lawsuit Over Dropping Zepbound
|
Written by: J. Smith |
Hits: 254
|
|
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
|
Written by: J. Smith |
Hits: 460
|
|
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
|
Written by: J. Smith |
Hits: 362
|
|
Teva Launches First Generic GLP-1 for Obesity
|
Written by: J. Smith |
Hits: 249
|
|
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
|
Written by: J. Smith |
Hits: 286
|
|
FDA Expands Repatha Access to More High-Risk Adults
|
Written by: J. Smith |
Hits: 427
|
|
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
|
Written by: J. Smith |
Hits: 466
|
